Keywords: Eli Lilly, Strides Arcolab, Cancer drugs, Emerging markets, Branded generics

Eli Lilly in deal with Strides Arcolab for cancer drugs in emerging markets

Article | 06 December 2012

Print This

US pharma major Eli Lilly (NYSE: LLY) and Indian drugmaker Strides Arcolab (BO: 532531) have entered into a collaboration to expand ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in